Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ruxolitinib combined with decitabine-intensified modified busulfan/cyclophosphamide conditioning regimen reduces relapse after allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWeiqi Li

Discussion

Loading...

Member takes

Overview

Prospective trial shows Ruxolitinib and decitabine reduce relapse in AML post-transplant, indicating enhanced safety and efficacy.

Key Points

  • Cumulative recurrence rate one year after transplantation was just 5.26% for acute myeloid leukemia patients.
  • Overall survival rate reached 90.4% within one year, and progression-free survival rate was 87.5%.
  • Observational analysis captures outcomes following the Rux-Dec-mBu/Cy regimen, enhancing anti-leukemia effects.
  • These findings suggest improved transplant outcomes may reduce toxicity, supporting Rux-Dec-mBu/Cy as a viable alternative.

Cite This Study

Weiqi Li (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db48https://doi.org/10.1182/blood-2025-5969
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ruxolitinib and decitabine plus a busulfan–cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes2025
  2. 2An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation2025
  3. 3Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia2025
  4. 4Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial2025
  5. 5Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation2025 · 6 citations